Simvastatin-treated OVA+LPS mice had reduced features of asthma as compared to PBS-treated counterparts, with reduced airway hyperresponsiveness (Figure 1(a)); lower BALF total cell and neutrophil counts (Figures 1(b) and 1(d)); reduced concentrations of BALF IL-4, IL-1β, INF-γ, and IL-17A (Figures 1(e)–1(h)); reduced perivascular and peribronchial leukocyte infiltration (Figures 1(i) and 1(j)); less mucus production (Figures 1(k) and 1(l)); and less lung Th2 and Th17, but higher percentage of Treg cells (Figures 1(m)–1(r)). This evidence concerns the gene IL17A and asthma.